Post-treatment lymphocytopaenia, integral body dose and overall survival in lung cancer patients treated with radical radiotherapy

Autor: Joseph, Nuradh, McWilliam, Alan, Kennedy, Jason, Haslett, Kate, Mahil, Jasmin, Gavarraju, Abhilash, Mistry, Hitesh, Van Herk, Marcel, Faivre-Finn, Corinne, Choudhury, Ananya

Publikováno v: In Radiotherapy and Oncology June 2019 135:115-119

Which patients with ES-SCLC are most likely to benefit from more aggressive radiotherapy: A secondary analysis of the Phase III CREST trial

Autor: Slotman, Ben J., Faivre-Finn, Corinne, van Tinteren, Harm, Keijser, Astrid, Praag, John, Knegjens, Joost, Hatton, Matthew, van Dam, Iris, van der Leest, Annija, Reymen, Bart, Stigt, Jos, Haslett, Kate, Tripathi, Devashish, Smit, Egbert F., Senan, Suresh

Publikováno v: In Lung Cancer June 2017 108:150-153

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Phase I trial evaluating MEK inhibitor selumetinib with concomitant thoracic radiotherapy in NSCLC

Autor: Haslett, Kate, Blackhall, Fiona, Koh, Pek, Asselin, Marie-Claude, Jackson, Alan, Manoharan, Prakhash, Ryder, W David, Taylor, B, Faivre-Finn, Corinne

Publikováno v: Haslett, K, Blackhall, F, Koh, P, Asselin, M-C, Jackson, A, Manoharan, P, Ryder, W D, Taylor, B & Faivre-Finn, C 2018, Phase I trial evaluating MEK inhibitor selumetinib with concomitant thoracic radiotherapy in NSCLC . in Radiotherapy and Oncology . vol. 127, PO-0753, pp. S387-S387 . https://doi.org/10.1016/j.jtho.2017.09.620

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______3818::e4f3185e60966b0449739b500d9fc0c1
https://www.research.manchester.ac.uk/portal/en/publications/phase-i-trial-evaluating-mek-inhibitor-selumetinib-with-concomitant-thoracic-radiotherapy-in-nsclc(ceced8d8-e920-4255-a3a6-ca0549d64760).html